Brokers Set Expectations for Genomic Health, Inc.’s FY2017 Earnings (GHDX)

Genomic Health, Inc. (NASDAQ:GHDX) – Stock analysts at Jefferies Group lowered their FY2017 earnings per share estimates for shares of Genomic Health in a report released on Thursday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will earn ($0.09) per share for the year, down from their previous forecast of $0.01. Jefferies Group has a “Hold” rating and a $34.00 price objective on the stock.

TRADEMARK VIOLATION NOTICE: “Brokers Set Expectations for Genomic Health, Inc.’s FY2017 Earnings (GHDX)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/14/brokers-set-expectations-for-genomic-health-inc-s-fy2017-earnings-ghdx.html.

Several other equities research analysts have also recently issued reports on GHDX. Zacks Investment Research cut Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Piper Jaffray Companies reiterated a “hold” rating and issued a $31.00 price target on shares of Genomic Health in a research note on Thursday, August 3rd. BidaskClub cut Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Canaccord Genuity cut their price target on Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 15th. Finally, Cowen and Company reiterated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. Genomic Health currently has a consensus rating of “Hold” and an average target price of $32.00.

Shares of Genomic Health (GHDX) opened at $28.59 on Monday. Genomic Health has a 12 month low of $26.37 and a 12 month high of $34.02.

In other news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total transaction of $159,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Insiders have sold 21,379 shares of company stock valued at $676,131 over the last quarter. Company insiders own 46.20% of the company’s stock.

Several large investors have recently made changes to their positions in GHDX. Bank of New York Mellon Corp increased its holdings in Genomic Health by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock valued at $2,789,000 after purchasing an additional 500 shares during the period. American International Group Inc. increased its holdings in Genomic Health by 7.1% in the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock valued at $362,000 after purchasing an additional 765 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Genomic Health by 5.6% in the first quarter. TIAA CREF Investment Management LLC now owns 71,233 shares of the medical research company’s stock valued at $2,243,000 after purchasing an additional 3,808 shares during the period. Legal & General Group Plc increased its holdings in Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 2,038 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Genomic Health by 8.8% in the first quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock valued at $49,256,000 after purchasing an additional 126,807 shares during the period. Institutional investors own 89.13% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply